IPP Bureau
Granules India bags EcoVadis’ Gold Rating
By IPP Bureau - May 08, 2025
The company's first-ever corporate-level submission to EcoVadis builds on years of operational and environmental excellence
AstraZeneca's enhertu improved pCR in early-stage breast cancer
By IPP Bureau - May 07, 2025
AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of care
Europe (AGES, Austria) inspects Shilpa Biologicals’ Dharwad site
By IPP Bureau - May 06, 2025
he inspection covering the sterile drug product filling and packaging line, quality systems and quality control laboratories concluded compliance with the principles and guidelines of Good Manufacturing Practice
Briefs: Tatva Chintan Pharma Chem and Shelter Pharma
By IPP Bureau - May 06, 2025
Tatva Chintan Pharma Chem receives export order worth $35, 55,000
Ichnos Glenmark Innovation receives USFDA fast track designation for ISB 2001 for relapsed/refractory multiple myeloma
By IPP Bureau - May 06, 2025
IGI recently completed the dose-escalation portion of its Phase 1 clinical study in patients with heavily pretreated multiple myeloma
GMM Pfaudler Group appoints Gregory Gelhaus as Chief Transformation Officer
By IPP Bureau - May 06, 2025
Gelhaus has a proven track record of driving business growth
Senores Pharmaceuticals acquires ANDA for Topiramate HCl 25, 50, 100 and 200 mg tablets
By IPP Bureau - May 06, 2025
Topiramate is indicated as a treatment of epilepsy and migraine
Alembic Pharmaceuticals posts Q4 FY25 consolidated PAT at Rs. 156.63 Cr
By IPP Bureau - May 06, 2025
The company has posted net profit of Rs. 582.01 crores for the Financial Year ended March 31, 2025
Innoxel Lifesciences completes USFDA inspection
By IPP Bureau - May 06, 2025
This outcome reflects Innoxel Lifesciences' ongoing commitment to maintaining the highest standards of quality, compliance, and regulatory excellence
OneSource Specialty Pharma reports consolidated Q4 FY25 PAT at Rs. 98.50 Cr
By IPP Bureau - May 06, 2025
The company has posted net loss of Rs. 17.97 crores for the Financial Year ended March 31, 2025
Ami Organics Q4 FY25 PAT up at Rs. 62.48 Cr
By IPP Bureau - May 05, 2025
The company has posted net profit of Rs. 158.71 crores for the Financial Year ended March 31, 2025
Tatva Chintan Pharma Chem reports consolidated Q4 FY25 PAT at Rs. 1.03 Cr
By IPP Bureau - May 05, 2025
The company has posted net profit of Rs.5.71 crores for the Financial Year ended March 31, 2025
Roquette completes acquisition of IFF Pharma Solutions
By IPP Bureau - May 05, 2025
The transaction enhances Roquette’s ability to deliver high-value drug delivery solutions to pharmaceutical customers worldwide
Biocon Biologics secures strong market coverage for Yesintek in US
By IPP Bureau - May 05, 2025
Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025
